A retrospective study of the management of oral mucous membrane pemphigoid with dapsone

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 88, Issue 2, 1999, Pages 159-163

  Ciarrocca, Katharine N ^a,b,c  

^a School of Veterinary Medicine   (United States)

^b Department of Oral Medicine ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DAPSONE; FLUOCINONIDE; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG COMBINATION; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; MALE; MIDDLE AGED; MOUTH DISEASE; MOUTH MUCOSA; MUCOUS MEMBRANE PEMPHIGOID; PATHOLOGY; REMISSION; RETROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DAPSONE; DRUG COMBINATIONS; FEMALE; FLUOCINONIDE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; MOUTH MUCOSA; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033173615     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(99)70110-1     Document Type: Article

References (28)

1. Greenberg MS. Ulcerative, vesicular, and bullous lesions. In: Lynch MA, Brightman VJ, Greenberg MS, editors. Burket's oral medicine. 9th ed. Philadelphia: JB Lippincott: 1994. p. 37-9.
2. Vincent SD, Lilly FE, Baker KA. Clinical, historic, and therapeutic features of cicatricial pemphigoid. Oral Surg Oral Med Oral Pathol 1993;76:453-9.
3. Ahmed AR, Kurgis BS, Rogers RS. Cicatricial pemphigoid. J Am Acad Dermatol 1991;24:987-1001.
4. Bernard R, Prost C, Lecerf V, et al. Studies of cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis. J Invest Dermatol 1990;94:630-5.
5. Leenutaphong V, von Kries R, Plewig G. Localized cicatricial pemphigoid (Brunsting-Perry): electron microscopic study. J Am Acad Dermatol 1989;21:1089-93.
6. Chan LS, Majmudar AA, Tran HH, Meier F, et al. Laminin-6 and Laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 1997;108:848-53.
7. Allbritton JI, Nousari HC, Anhalt GJ. Antiepiligrin (laminin-5) cicatricial pemphigoid. Br J Dermatol 1997;137:992-6.
8. Lozada-Nur F, Miranda C, Maliksi R. Double-blind clinical trial of 0.05% clobetasol proprionate ointment in orabase and 0.05% fluocinonide ointment in vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1994;77:598-604.
9. Rogers RS, Seehafer JR, Perry HO. Treatment of pemphigoid with dapsone. J Am Acad Dermatol 1982;6:215-23.
10. Rogers RS, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Seminars in Dermatology 1988;7:201-5.
11. Lamey PJ, Ress TD, Binnie WH, Rankin KV. Mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol 1992;74:50-3.
12. Lee BL, Medina I, Benowitz NL, et al. Dapsone, trimethoprim and sulfamethoxazole plasma levels during treatment of pneumocystis pneumonia in patients with AIDS: evidence of drug interactions. Ann Intern Med 1989;110:606-11.
13. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993;129:507-13.
14. Matthews RN, Pinkney RCN, Scully C. The management of intransigent desquamative gingivitis with dapsone. Ann Dent 1989;48:41-3.
15. DeGowin RL. A review of therapeutic and hemolytic effects of dapsone. Arch Intern Med 1967;120:242-8.
16. Hall RP. Dermatitis herpetiformis. J Invest Dermatol 1992;99:873.
17. Nguyen QD, Foster CS. Cicatricial pemphigoid: diagnosis and treatment. Int Ophthalmol Clin 1996;36:41-60.
18. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997;62:827-36.
19. Booth SA, Moody CE, Dahl MA, Herron MJ, Nelson RD. Dapsone suppresses integrin mediated neutrophil adherence function. J Invest Dermatol 1992;98:135-40.
20. Eversole LR. Immunopathology of oral mucosal ulcerative, desquamative, and bullous diseases. Oral Surg Oral Med Oral Pathol 1994;77:555-71.
21. Sciubba JJ. Autoimmune aspects of pemphigus vulgaris and mucosal pemphigoid. Adv Dent Res 1996;10:52-6.
22. Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996;35:346-9.
23. Cucinell SA, Israeli ZH, Dayton PG. Microsomal N-oxidation of dapsone as a cause of methaemoglobin formation in human red cells. Am J Trop Med Hyg 1972;21:322-31.
24. Grossman SJ, Jollow DJ. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther 1988;244:118-25.
25. Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995;26:1461-7.
26. Coleman MD, Rhodes IE, Scott AK, et al. The use of cimetidine to reduce dapsone-dependent methaemoglobinemia in dermatitis herpetiformis patients. Br J Pharmacol 1992;34:244-9.
27. Rhodes LE, Tingle MD, Park BK, Chu P, Verbov JL, Friedmann PS. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol 1995;132:257-62.
28. Foster CS, Neumann R, Tauber J. Long term results of systemic chemotherapy for ocular pemphigoid. Doc Ophthalmol 1992;82:223-9.